drugset / Trial / NCT05313074
SARS-CoV-2 Specific Immune Response After COVID-19 Vaccination in Cancer Patients
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Our study highlights a low degree of neutralization-afforded protection mounted by CoronaVac in cancer patients when compared with healthy volunteers, especially patients who received chemotherapy. Further booster doses, beyond the conventional two-dose regimen might be needed for recipients of CoronaVac to maintain a long-term anamnestic response.
Timeline
- Start
- 2021-03-23
- Primary completion
- 2022-02-25
- Completion
- 2022-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CoronaVac vaccine | Vaccine | — | — |